Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpineStim is an early-stage regenerative medicine and medical device company developing bioelectric stimulation systems for spinal cord injury recovery. The company states that its spinal cord stimulator systems are intended not only to address chronic pain but also to promote nerve and muscle regeneration by modulating protein expression and inflammation. Its technology appears to combine bioelectric stimulation with regenerative biologics, including a concept called SpineStim Plus Biologics that incorporates an implantable refillable micro-infusion system and a proprietary biologic formulation. SpineStim is associated with the Leonhardt Ventures ecosystem and is led by Howard Leonhardt. The company remains investigational and explicitly states that its products are not yet proven safe or effective.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SpineStim.